Deliver the A-share market information at the first time, observe the market trend, grasp the rise and fall logic and tap investment opportunities.
a shares “sound up”! Leading collective protection repurchase and increase in holdings
On March 10, A-Shares “Rose”. Plate, medicine, automobiles, building materials, lithium batteries, Baijiu, photovoltaic sector gains.
In terms of news, recently, leaders in subdivided industries led by Kweichow Moutai Co.Ltd(600519) took the initiative to disclose monthly business data. From the data disclosed, the performance of companies such as Wuxi Apptec Co.Ltd(603259) , Shanxi Xinghuacun Fen Wine Factory Co.Ltd(600809) , Tongwei Co.Ltd(600438) , National Silicon Industry Group Co.Ltd(688126) , Jiangsu King’S Luck Brewery Joint-Stock Co.Ltd(603369) , Guangzhou Tinci Materials Technology Co.Ltd(002709) , Beijing Easpring Material Technology Co.Ltd(300073) .
It is worth noting that this is also the “first time in history” for leaders such as Kweichow Moutai Co.Ltd(600519) to disclose monthly main business data.
Sealand Securities Co.Ltd(000750) said that the monthly operating data disclosed by Maotai for the first time had greatly exceeded the expected performance, which had a great boost to the market sentiment. Other listed companies have followed the pre Hi, and the overall market atmosphere is expected to pick up.
At the same time, listed companies have set off a wave of “repurchase and shareholding increase”. According to statistics, since this month, a total of 112 listed companies have disclosed their repurchase plans. The repurchase scale of Tianfeng Securities Co.Ltd(601162) , Foxconn Industrial Internet Co.Ltd(601138) , 360 Security Technology Inc(601360) and others ranks among the top. Among them, 360 Security Technology Inc(601360) said that it plans to repurchase the company’s shares by means of centralized bidding in the next three trading days, with a total repurchase amount of no less than 90 million yuan and no more than 120 million yuan.
In addition, recently, many companies announced to increase their holdings, and Thunder Software Technology Co.Ltd(300496) , Zhejiang Hangmin Co.Ltd(600987) , Zhejiang Dingli Machinery Co.Ltd(603338) , Betta Pharmaceuticals Co.Ltd(300558) and other companies have issued announcements on increasing their holdings. Among them, Thunder Software Technology Co.Ltd(300496) announced that Zou Pengcheng, vice chairman of the company, Wang Huanxin, director, chief financial officer and Secretary of the board of directors, and Sun Tao, deputy general manager, planned to increase their holdings of the company’s shares through centralized bidding, block trading or other means permitted by laws and regulations within 6 months from the date of the announcement. Zou Pengcheng and Wang Huanxin each increased their shares by no less than 6 million yuan, and Sun Tao increased their shares by no less than 3 million yuan.
Baijiu sector strong rebound Shanxi Xinghuacun Fen Wine Factory Co.Ltd(600809) rose 8% before two months net profit increased by over 50
Recently, the weak Baijiu sector rebounded strongly in 10 days, as of press release, Anhui Golden Seed Winery Co.Ltd(600199) trading, Shanxi Xinghuacun Fen Wine Factory Co.Ltd(600809) rose more than 8% close to 300 yuan mark, Jiugui Liquor Co.Ltd(000799) , Shede Spirits Co.Ltd(600702) , Luzhou Laojiao Co.Ltd(000568) , Xinjiang Yilite Industry Co.Ltd(600197) and other gains rose, Kweichow Moutai Co.Ltd(600519) rose nearly 2% to return to 1800 yuan above. In addition, Chongqing Brewery Co.Ltd(600132) , Tsingtao Brewery Company Limited(600600) also strengthened.
On the 9th, Shanxi Xinghuacun Fen Wine Factory Co.Ltd(600809) disclosed the operation from January to February 2022. In 2022, the company continued to gather brand potential energy and comprehensively improve operation efficiency. Each sales area overcame the impact of the epidemic and arranged the peak season of the Spring Festival ahead of schedule. The overall market sales were good. Medium and high-end products such as Qinghua Fenjiu series achieved a significant growth, and the operating revenue and net profit reached the best level in history. After preliminary accounting, from January to February 2022, the company is expected to achieve a total operating revenue of more than 7.4 billion yuan, with a year-on-year increase of more than 35%; The net profit attributable to shareholders of listed companies is expected to be more than 2.7 billion yuan, with a year-on-year growth rate of more than 50%.
In this regard, Southwest Securities Co.Ltd(600369) said that the company took the initiative to control the goods and sort out the channels in the fourth quarter of 2021, so as to store energy ahead of the Spring Festival in 2022. During the Spring Festival in 2022, relying on Risheng’s brand potential, the company overcame the adverse impact of the national sporadic epidemic outbreak, upgraded the product structure and expanded nationwide, and made a good start as scheduled.
In the case of macroeconomic pressure and sporadic outbreak of the epidemic, the company fulfilled its expectations of a good start and growth toughness as scheduled; Looking forward to the whole year, the company’s product structure will blossom at many points, and the nationwide expansion is unstoppable. It has both stability and growth, and the growth rate will continue to lead the first-line famous wines. The brand potential of the company continues to be released. Qinghua 20 has obvious advantages in brand power and channel power at the secondary high-end price of 400 yuan, and the high growth can be expected throughout the year; With the comprehensive replacement of the old version of blue and white 30 by the Renaissance version, the company has strengthened the cultivation of the Renaissance version, and the growth rate of the Renaissance version can be expected; In addition, Panama and laobaifen at the waist continued their steady growth, while Bofen and Zhuyeqing performed commendably and had full determination for steady growth.
On March 7, Kweichow Moutai Co.Ltd(600519) disclosed the main business data from January to February 2022, which showed that during the Spring Festival in 2022, the sales momentum of the company’s products was good, the market showed a booming trend, and the company successfully achieved a “good start”. According to the preliminary accounting of the company, from January to February 2022, the company achieved a total operating revenue of about 20.2 billion yuan, an increase of about 20% year-on-year; The net profit attributable to shareholders of listed companies was about 10.2 billion yuan, an increase of about 20% year-on-year.
In this regard, Guotai Junan Securities Co.Ltd(601211) Securities pointed out that the company’s peak season sales achieved a good start, and its performance accelerated to exceed market expectations, laying a sound foundation for the completion of tasks throughout the year. From the perspective of splitting, the quota implementation progress of large single product Feitian from January to February is expected to be about 25-30% (according to the grass-roots research, the progress is expected to be slightly faster and the base number is higher from January to February 2021). The contribution increment of non-standard products and Maotai 1935 is expected to be about 5% of the income increment. Considering the price increase of non-standard products and the increase of the proportion of self operated products after channel reform, the contribution increment is expected to be obvious.
For Baijiu Baijiu, Qianhai securities of East Asia pointed out that since 2022, the liquor sector PE has been declining, mainly due to the impact of repeated epidemic, geopolitical factors and consumption tax expectations. The valuation callback stems from the increase of its industry attributes and liquidity relevance, and the reconstruction of Baijiu liquor valuation system in the new stage is vulnerable to the global financial risk factors and the fluctuation of capital. In the long run, Baijiu industry has no worries.
The industry is still in a business cycle, and the structural differentiation driven by consumption upgrading may continue under the trend of volume reduction and price increase. The high-end famous liquor has sufficient toughness. Under the multiple reforms of production capacity, corporate governance and product structure, Maotai has absolute brand advantages superimposed on the good expectations of marketization, and has strong certainty of steady growth in performance Wuliangye Yibin Co.Ltd(000858) personnel changes are implemented, and the superimposed later volume control and price support may support the upward rating. The valuation has been discounted, so there are layout opportunities. The layout on the left focuses on the elastic space brought by the growth of secondary high-end. The performance of sub high-end liquor enterprises will achieve high growth in 2021. The market expects that the growth rate will be under pressure in the second quarter of 2022. However, from a longer perspective, the epidemic will eventually stabilize, the consumption scene will be replenished and the consumption will be upgraded. There is a large elastic space under the continuation of the growth rate of sub high-end capacity expansion.
multiple segments lead a shares pharmaceutical shares spring is coming again
On March 10, pharmaceutical related stocks such as pharmaceutical business and pharmaceutical e-commerce opened significantly higher. As of press time, China Meheco Group Co.Ltd(600056) , Qingdao Baheal Medical Inc(301015) , Hpgc Renmintongtai Pharmaceutical Corporation(600829) , Luyan Phapma Co.Ltd(002788) and other stocks rose by the limit, Cachet Pharmaceutical Co.Ltd(002462) , Shanghai Kaikai Industry Company Limited(600272) , Sichuan Hezong Medicine Easy-To-Buy Pharmaceutical Co.Ltd(300937) .
China Meheco Group Co.Ltd(600056) 9 announced the announcement of Pfizer’s Pfizer’s COVID-19 virus therapeutic drug NAT Matt / Ritonavir Tablets composite packaging (Paxlovid) in 2022, and is in the Chinese mainland market. On February 11, the State Drug Administration conducted emergency review and approval in accordance with the relevant provisions of the drug administration law and the special drug approval procedures, and approved the import registration of Pfizer’s products with conditions.
In the secondary market, the medical and health industry experienced a significant retreat in 2021. In January this year, the decline of relevant sectors was still fierce, and finally ushered in a rebound in mid February. For the follow-up trend of the pharmaceutical sector, Hua’an Fund believes that after the early adjustment, the negative factors of the sector have been fully released. Dongzheng asset management believes that companies that comply with current policies, have the fastest industrial development and the fastest growth rate will become the outlet of the market and the source of excess returns.
Great Wall Guorui Securities pointed out that the current investment value of the pharmaceutical industry is prominent and the valuation is at the bottom of history. It is suggested to increase the allocation proportion of the industry and pay attention to investment opportunities in six aspects:
First, the performance of the annual report of 2021 and the first quarterly report of 2022 is about to be disclosed, and pay attention to the high-quality targets that the performance of the annual report and the first quarterly report is expected to grow high or exceed expectations;
Second, with the official release of the 14th five year plan for the development of pharmaceutical industry, under the premise of controlling medical insurance expenses, innovation and internationalization will be the core main line of the industry in the future. It is suggested to pay attention to innovation driven companies and pharmaceutical enterprises with international ability;
Third, the CXO industry. Recently, the CXO industry has undergone in-depth adjustment, and the valuation is at the bottom of history. Contrarian, focus on companies with sufficient orders and reasonable current valuation;
Fourth, drugstore chain companies with reasonable valuation and stable recovery;
Fifth, pay attention to the consumer medical sector. Under the background of medical insurance fee control, the ophthalmology, medical beauty and other medical sub industries with consumption attribute have policy immunity, and the consumption upgrading will drive their development;
Sixth, pay attention to the traditional Chinese medicine sector. The release of the guiding opinions on medical insurance supporting the inheritance, innovation and development of traditional Chinese medicine shows the state’s determination to the inheritance, innovation and development of traditional Chinese medicine, which will play a positive role in the traditional Chinese medicine industry.
234564567 \\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\ many provinces and cities have explicitly included assisted reproduction in medical insurance
The concept of assisted reproduction rose strongly in the session on the 10th. As of press time, Tianjin Tianyao Pharmaceutical Co.Ltd(600488) , Changjiangrunfa Health Industry Co.Ltd(002435) limit rose, and hot biology, Seto biology, Suzhou Medicalsystem Technology Co.Ltd(603990) , Huapont Life Sciences Co.Ltd(002004) and other gains were ahead. It is worth noting that Changjiangrunfa Health Industry Co.Ltd(002435) has been trading for five consecutive trading days.
Recently, the Beijing Municipal Medical Insurance Bureau, the Beijing Municipal Health Commission and the Beijing Municipal Human Resources and Social Security Bureau jointly issued the notice on standardizing the adjustment of some medical service price items, standardized the adjustment of 63 medical service price items, and included 16 auxiliary reproductive items common in outpatient treatment into the category a reimbursement scope of medical insurance, including designated institutions of public and non-public medical insurance, It will be officially implemented on March 26.
In addition, recently, Hunan Province and Sichuan Provincial Health Commission have made it clear on the official platform that they will gradually explore the inclusion of common assisted reproductive technology projects with mature technology, safety and reliability and controllable cost into the scope of medical insurance reimbursement.
Some institutions said that assisted reproduction reflects the value of doctors’ technology and services, so the risk of price reduction is limited for the core technical service links. At present, the average cost of IVF in a single cycle in China is about 3500045000 (excluding the third generation). This time, it has entered the medical insurance, and the medical insurance coverage is about 800011000 yuan. Recently, the state has made frequent policies to encourage childbirth, and assisted reproductive projects are expected to include medical insurance payment in more areas in the future.
Galaxy Securities pointed out that in 2018, about 568000 patients in China received assisted reproductive services, accounting for only 1.2% of 47.8 million infertile couples in the same year. At present, China has the same infertility rate as developed countries, but there is still a big gap in the proportion of people receiving assisted reproductive services. Statistics show that the penetration rate of assisted reproduction in China in 2018 was only 7.0%, much lower than 30.2% in the United States in the same period. In the future, with the deepening of people’s understanding of assisted reproductive technology, the increase of per capita disposable income and the liberalization of policies to encourage fertility, the penetration rate of assisted reproductive technology in China is expected to continue to increase.
Ping An Securities said that the entry of assisted reproductive projects into medical insurance will accelerate the development of the industry, and the downstream medical service enterprises will take the lead in benefiting. China’s assisted reproductive drug market is still dominated by imports. If the drug market is intensively purchased in the future, it is expected to promote the reconstruction of the market competition pattern and bring opportunities to domestic pharmaceutical enterprises. It is suggested to pay attention to: Jinxin reproduction, Beikang medical treatment, Changchun High And New Technology Industries (Group) Inc(000661) , Livzon Pharmaceutical Group Inc(000513) .
some cement enterprises issue price increase notice focus on regional leading enterprises (with shares)
Recently, cement prices in some parts of China have continued to rise. According to chinacement.com, at present, some enterprises along the Yangtze River in Anhui are still stopping kilns for maintenance, and the clinker inventory is running at a low level. At the same time, it is driven by the increase of raw material prices. Since March 9, some major enterprises along the river have been notified to increase the clinker price by about 30 yuan / ton in the fourth round. In addition, the market demand in Wuhan, Hubei Province has been recovering recently, and the delivery of some enterprises can reach about 70-80%. In order to improve profits, major manufacturers in the region plan to raise the cement price by about 20-30 yuan / ton on the 10th.
China Merchants Securities Co.Ltd(600999) pointed out that the national cement price index rose, and the cement price index rose in most regions such as the Yangtze River, North China, East China and southwest China.
The rise of coal and clinker prices has driven the recent rise of cement prices to a certain extent. At the same time, the peak production or kiln shutdown for maintenance has led to the low clinker inventory. From the perspective of industry fundamentals, the performance forecast profit of sector enterprises in 2021 is mostly negative growth, which makes the cement at the bottom of the cycle and the valuation is low. In March, with the arrival of the peak construction season, the cement price is expected to enter the upward channel. It is recommended to pay attention to the sector opportunities.
Sealand Securities Co.Ltd(000750) believes that in the short term, despite the slow recovery of downstream demand at the beginning of the market, driven by the rise of the cost side, the upward trend of cement prices in various regions is obvious. It is expected that in March, with the continuous increase of downstream demand, cement prices in most regions will begin to rebound. At present, it is recommended to take the lead in the cement area Anhui Conch Cement Company Limited(600585) , Gansu Shangfeng Cement Co.Ltd(000672) , focusing on Huaxin Cement Co.Ltd(600801) , Xinjiang Tianshan Cement Co.Ltd(000877) .
2022 mid year Japan Forum on pollution reduction, carbon reduction and hydrogen energy development was held in Qiong hydrogen energy industry has huge development space
The “2022 China Japan Forum on pollution reduction, carbon reduction and hydrogen energy development” was held in Haikou on March 9, Hainan Daily reported. Shi Dinghuan, chairman of the expert committee of the energy investment committee of the China Investment Association, pointed out that the development of hydrogen energy has attracted increasing attention from all countries. Hainan Province has also formulated the “14th five year plan” for hydrogen energy development, and Japan has always been in the forefront of the world in terms of hydrogen energy development. Hainan free trade port has superior policies and business environment, which is conducive to relevant cooperation between China and Japan.
Jia Bingjun, chairman of Datang Hainan Energy Development Co., Ltd., introduced the company’s deep integration into the construction of Hainan clean energy island. It is reported that Datang Hainan Company will take “green hydrogen” as the development core and realize the application in multiple application scenarios such as transportation, energy, energy storage and power generation; Foster and promote the implementation of hydrogen energy industry projects in photovoltaic, offshore wind power hydrogen production, gas turbine waste heat hydrogen production, biomass hydrogen production, hydrogen production and hydrogenation station cooperation.
Dongguan Securities pointed out that the demand for hydrogen energy has accelerated and the development space of hydrogen energy industry is huge. In 2020, China’s hydrogen demand will be about 33.42 million tons. By 2030, China’s annual hydrogen demand will increase to 37.15 million tons, accounting for about 5% of the terminal energy consumption. By 2060, China’s annual hydrogen demand will increase to about 130 million tons, accounting for about 20% of the terminal energy consumption. China’s hydrogen demand will gradually increase in the future. As other large central enterprises enter the hydrogen energy industry, the market concentration of the hydrogen energy industry is expected to increase in the future. At present, more than one-third of central enterprises are in the layout of the whole industrial chain, including hydrogen production, hydrogen storage, hydrogenation, hydrogen use and so on. There is a huge space for the development of hydrogen energy industry.
